A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

COLONIE — Latham-based medical technology company AngioDynamics is ramping up marketing of its NanoKnife cancer treatment machine after receiving approval from the U.S. Food and Drug Administration ...

Repurposed Drug use for cancer is exploding around the world. And today, New Year’s Day 2025, even Artificial Intelligence is ...

Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug ...

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success ...

EXCLUSIVE - Cruel bladder cancer may have found a determined new adversary after an experimental drug have proven to not only ...

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

Researchers found that prostate cancer patients with greater socioeconomic disadvantages were less likely to receive targeted therapy, and participation in the 340B program did not counteract that.

Gifts in Wills fund one-third of Cancer Research UK’s work. Work that supports life-saving trials for people like Alfred.

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...